Want to see IN:ROSSARI full AI Analyst Report?
Top Page
Rossari Biotech Ltd
(ROSSARI)
Select Model
Select Model
Rating:57Neutral
Price Target:
₹477.00
â–¼(-18.31% Downside)
Action:Reiterated
Date:08/09/26
The score is held back primarily by weak cash generation (volatile operating cash flow and persistently negative, deeply negative 2026 free cash flow) and some 2026 margin pressure, despite steady revenue growth and an otherwise reasonably healthy balance sheet. Technicals are mixed with slightly negative momentum, while valuation is moderate but not strongly supported by the very low dividend yield.
Positive Factors
Steady revenue growth
Revenue expansion from 2021 through 2026, alongside reported revenue growth of 19.5%, indicates continued demand across the company’s specialty-chemical offerings. A broader revenue base can support operating leverage, customer development and reinvestment over the next several quarters, even as growth moderates.
Negative Factors
Weak cash conversion
Volatile operating cash flow and deeply negative 2026 free cash flow show that reported earnings are not consistently converting into usable cash. This can restrict internal funding for expansion, increase dependence on borrowing, and reduce the company’s flexibility if investment or working-capital needs remain elevated.
Read all positive and negative factors
Positive Factors
Negative Factors
Steady revenue growth
Revenue expansion from 2021 through 2026, alongside reported revenue growth of 19.5%, indicates continued demand across the company’s specialty-chemical offerings. A broader revenue base can support operating leverage, customer development and reinvestment over the next several quarters, even as growth moderates.
Read all positive factors
Rossari Biotech Ltd (ROSSARI) vs. iShares MSCI India ETF (INDA)
Market Cap
₹25.53B
Dividend Yield0.11%
Average Volume (3M)5.04K
Price to Earnings (P/E)16.9
Beta (1Y)1.11
Revenue Growth19.47%
EPS Growth11.49%
CountryIN
Employees585
SectorGeneral
Sector StrengthN/A
IndustryChemicals - Specialty
Share Statistics
EPS (TTM)27.22
Shares Outstanding55,394,115
10 Day Avg. Volume5,087
30 Day Avg. Volume5,043
Financial Highlights & Ratios
PEG Ratio1.51
Price to Book (P/B)1.57
Price to Sales (P/S)0.87
P/FCF Ratio-9.55
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)26.7
Revenue Forecast (FY)₹26.52B
Rossari Biotech Ltd Business Overview & Revenue Model
Company Description
Rossari Biotech Limited, an India-based company, is a global manufacturer and distributor of specialized chemical products. Its diverse offerings cater to numerous industries, including ingredients for soaps and detergents, formulations for inks, ...
How the Company Makes Money
Rossari Biotech makes money primarily by selling specialty chemical formulations and allied solutions to business customers (B2B). Its revenue model is driven by: (1) Product sales across application categories: The company supplies textile specia...
Rossari Biotech Ltd Financial Statement Overview
Summary
Income Statement
63
Positive
Balance Sheet
72
Positive
Cash Flow
34
Negative
| Breakdown | TTM | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 25.50B | 23.96B | 20.80B | 18.31B | 16.56B | 14.83B |
| Gross Profit | 5.83B | 4.94B | 6.47B | 5.26B | 2.80B | 2.29B |
| EBITDA | 3.24B | 2.86B | 2.65B | 2.57B | 2.12B | 1.94B |
| Net Income | 1.51B | 1.49B | 1.36B | 1.31B | 1.07B | 976.74M |
Balance Sheet | ||||||
| Total Assets | 0.00 | 22.89B | 18.96B | 15.72B | 13.68B | 12.57B |
| Cash, Cash Equivalents and Short-Term Investments | 1.15B | 1.27B | 1.14B | 667.85M | 1.52B | 644.26M |
| Total Debt | 0.00 | 4.36B | 2.18B | 1.19B | 739.28M | 84.27M |
| Total Liabilities | -13.33B | 9.55B | 7.11B | 5.24B | 4.52B | 4.52B |
| Stockholders Equity | 13.33B | 13.33B | 11.85B | 10.48B | 9.15B | 8.05B |
Cash Flow | ||||||
| Free Cash Flow | -1.67B | -2.20B | -210.69M | -880.28M | 1.20B | -88.67M |
| Operating Cash Flow | -250.32M | 451.63M | 1.37B | 432.55M | 1.52B | 293.58M |
| Investing Cash Flow | -1.06B | -2.22B | -1.84B | -1.03B | -1.81B | -2.99B |
| Financing Cash Flow | 1.22B | 2.09B | 649.01M | 161.85M | 608.55M | 2.92B |
Rossari Biotech Ltd Technical Analysis
Negative
583.95
Price Trends
506.36
Negative
510.70
Negative
518.27
Negative
Market Momentum
-12.25
Positive
28.39
Positive
12.42
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:ROSSARI, the sentiment is Negative. The current price of 583.95 is above the 20-day moving average (MA) of 491.00, above the 50-day MA of 506.36, and above the 200-day MA of 518.27, indicating a bearish trend. The MACD of -12.25 indicates Positive momentum. The RSI at 28.39 is Positive, neither overbought nor oversold. The STOCH value of 12.42 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for IN:ROSSARI.
Rossari Biotech Ltd Peers Comparison
UnderperformOutperform
Sector (55)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
69 Neutral | ₹59.98B | 43.08 | ― | 0.23% | 91.44% | 19.67% | |
68 Neutral | ₹76.69B | 21.77 | ― | 1.03% | 27.05% | 16.13% | |
63 Neutral | ₹81.88B | 39.76 | ― | 0.43% | 11.08% | 34.10% | |
62 Neutral | ₹36.44B | 0.58 | ― | 0.10% | 10.71% | 2756.39% | |
60 Neutral | ₹39.28B | 76.33 | ― | 0.06% | 41.09% | 618.16% | |
57 Neutral | ₹25.53B | 16.94 | ― | 0.11% | 19.47% | 11.49% | |
55 Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% |
* General Sector Average
IN:ROSSARI
Rossari Biotech Ltd
458.05
-157.20
-25.55%
IN:BALAMINES
Balaji Amines Limited
2,565.80
1,074.59
72.06%
IN:FCL
Fineotex Chemical Limited
56.66
33.27
142.23%
IN:GALAXYSURF
Galaxy Surfactants Ltd.
2,134.70
-184.41
-7.95%
IN:KIRIINDUS
Kiri Industries Limited
582.95
64.70
12.48%
IN:TATVA
Tatva Chintan Pharma Chem Limited
1,696.55
715.03
72.85%
Rossari Biotech Ltd Corporate Events
Rossari Biotech Sets July 20 Investor Call on Q1 FY27 Results
Jul 14, 2026
Rossari Biotech Ltd has scheduled an earnings conference call for investors and analysts to discuss its financial performance for the first quarter of fiscal year 2027. The call, to be held on Monday, July 20, 2026 at 5:00 p.m. IST, will include a...
Rossari Biotech Publishes AGM Notice and Details of E-Voting Facility
Jun 28, 2026
Rossari Biotech has notified exchanges that it has published the notice of its 17th Annual General Meeting in English and Marathi newspapers, outlining that the meeting will be held on July 20, 2026 at 11:00 a.m. via video conferencing or other au...
Rossari Biotech sets July 20 virtual AGM, proposes dividend and related-party approvals
Jun 26, 2026
Rossari Biotech Ltd has scheduled its 17th Annual General Meeting for July 20, 2026, to be held via video conferencing and other audio-visual means, in line with regulatory requirements and virtual meeting practices. The AGM agenda includes adopti...
Rossari Biotech Releases Integrated Sustainability Report for FY 2025-26
Jun 26, 2026
Rossari Biotech Limited has released its Business Responsibility and Sustainability Report for the financial year 2025-26, which now forms part of its integrated annual report and is available on the company’s website. The report underscores...
Rossari Biotech dispatches AGM, annual report access details to non-email shareholders
Jun 26, 2026
Rossari Biotech has informed stock exchanges that it has dispatched individual letters to shareholders whose email addresses are not registered, providing web links and a QR code to access the integrated annual report for the financial year 2025-2...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.